Skip to main content

FDA Approves New Combination Therapy for Type 2 Diabetes – Endocrinology Advisor

By May 20, 2019News
astrazeneca-logo

astrazeneca-logo

The Food and Drug Administration (FDA) has approved Qternmet XR (AstraZeneca) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D).

{iframe}https://www.endocrinologyadvisor.com/home/topics/diabetes/type-2-diabetes/fda-approves-new-combination-therapy-for-type-2-diabetes/{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.